片仔癀(600436.SH):擬在研究院下設成立新部門--藥材可持續利用與保護研究中心
格隆匯5月11日丨片仔癀(600436.SH)公佈,公司第六屆董事會第二十八次會議召開,審議通過《公司關於成立藥材可持續利用與保護研究中心的議案》;
根據公司戰略及可持續發展需要,為進一步做優做強做大公司的中藥材種養殖基地,有效構築並完善產業鏈管控模式,公司擬在研究院下設成立新部門--藥材可持續利用與保護研究中心,助推公司由單產品質量的競爭升級到全產業鏈質量管控的競爭。
藥材可持續利用與保護研究中心的主要職能:負責統籌、規劃、協調並開展公司中藥材種養殖的資源保護、道地藥材開發、規範化種養殖等工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.